See veebileht kasutab küpsiseid kasutaja sessiooni andmete hoidmiseks. Veebilehe kasutamisega nõustute ETISe kasutustingimustega. Loe rohkem
Olen nõus
"Muu" projekt MP1GI18084
MP1GI18084 "Soolestiku mikrobioomi roll tüüp II diabeedi ravimi metformiini metabolismis (1.09.2018−31.08.2021)", Elin Org, Tartu Ülikool, Tartu Ülikooli genoomika instituut.
MP1GI18084
Soolestiku mikrobioomi roll tüüp II diabeedi ravimi metformiini metabolismis
The interplay between gut microbiota and metformin treatment in type 2 diabetes
MBT2D
1.09.2018
31.08.2021
Teadus- ja arendusprojekt
Muu
ETIS klassifikaatorAlamvaldkondCERCS klassifikaatorFrascati Manual’i klassifikaatorProtsent
1. Bio- ja keskkonnateadused1.3. GeneetikaB220 Geneetika, tsütogeneetika 1.6 Bioteadused34,0
3. Terviseuuringud3.1. BiomeditsiinB726 Kliiniline bioloogia 3.1 Biomeditsiin33,0
4. Loodusteadused ja tehnika4.16. Biotehnoloogia (loodusteadused ja tehnika)T490 Biotehnoloogia 2.7 Keskkonnatehnika33,0
AsutusRiikTüüp
European Molecular Biology OrganizationSaksamaa Liitvabariik
PerioodSumma
01.09.2018−31.08.2021150 000,00 EUR
150 000,00 EUR
European Molecular Biology Organization

Gut microbiome have clear impact on modern metabolic diseases such as type 2 diabetes (T2D), obesity and metabolic syndrome. The gut microbiome is shaped by several factors arising from the host (genetics) and environment (diet, lifestyle, drug treatments etc), which in turn has a huge impact on our health. During the last years, I have explored host-­gut microbiota interactions in cardio-­metabolic traits in mice and human and showed how dietary and host genetic interactions control gut microbiome and influence host phenotypes. I will expand my previous research by exploring how the gut microbiome influences drug metabolism and nutrition. I will focus on pharmacology of metformin, commonly used drug for T2D treatment and study how the gut microbiota interaction with bile acid metabolism influences metformin metabolism and commonly observed side effect -­ gastrointestinal problems. To do so, I will utilize two human cohorts in this project. First is the METSIM population cohort collected by Dr. Markku Laakso, University of Kuopio, Finland, which consists of 10,000 men, that have been characterized in great detail for metabolic syndrome traits as well as for gut microbiota, metabolites, sequence variation and gene expression in adipose. Second is the Estonian Biobank cohort (around 52,000 participants) with detailed clinical and molecular datasets. In order to gain more comprehensive view of host-­microbial interactions, I will employ systems-­genetics approach by integrating microbiome data with available metabolomics and genomics datasets.
Gut microbiome have clear impact on modern metabolic diseases such as type 2 diabetes (T2D), obesity and metabolic syndrome. The gut microbiome is shaped by several factors arising from the host (genetics) and environment (diet, lifestyle, drug treatments etc), which in turn has a huge impact on our health. During the last years, I have explored host-­gut microbiota interactions in cardio-­metabolic traits in mice and human and showed how dietary and host genetic interactions control gut microbiome and influence host phenotypes. I will expand my previous research by exploring how the gut microbiome influences drug metabolism and nutrition. I will focus on pharmacology of metformin, commonly used drug for T2D treatment and study how the gut microbiota interaction with bile acid metabolism influences metformin metabolism and commonly observed side effect -­ gastrointestinal problems. To do so, I will utilize two human cohorts in this project. First is the METSIM population cohort collected by Dr. Markku Laakso, University of Kuopio, Finland, which consists of 10,000 men, that have been characterized in great detail for metabolic syndrome traits as well as for gut microbiota, metabolites, sequence variation and gene expression in adipose. Second is the Estonian Biobank cohort (around 52,000 participants) with detailed clinical and molecular datasets. In order to gain more comprehensive view of host-­microbial interactions, I will employ systems-­genetics approach by integrating microbiome data with available metabolomics and genomics datasets.
KirjeldusProtsent
Alusuuring100,0